Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Logothetis

Showing results (31-40 of 430) with videos related to

Pageof 43
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Is It Time to Re-Examine the Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases?Christopher J Logothetis, Ana M Aparicio
Nature Reviews. Cancer|January 5, 2005
Osteoblasts in prostate cancer metastasis to boneChristopher J Logothetis, Sue-Hwa Lin
Bibliotheca Psychiatrica|January 1, 1981
Side effects in preventive maintenance therapy with neuroleptics with special emphasis on tardive dyskinesiaJ Logothetis, A Paraschos, E Frangos
Cancer Research|August 4, 2004
Bortezomib as a potential treatment for prostate cancerChristos N Papandreou, Christopher J Logothetis
The American Journal of Psychiatry|February 1, 1981
The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapyN Manos, J Gkiouzepas, J Logothetis
Journal of the National Cancer Institute|July 22, 1998
Prospects for optimized clinical management of bladder cancer by application of phenotypic markersR E Millikan, C J Logothetis
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
High-grade prostate cancer and the prostate cancer prevention trialChristopher J Logothetis, Paul F Schellhammer
European Urology|March 27, 2024
Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7Christopher J Logothetis, Andrew W Hahn
European Urology|May 20, 2023
Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap SyndromeChristopher J Logothetis, Andrew W Hahn
Journal of the National Cancer Institute|November 18, 1992
Dose intensity in germ cell tumors: lessons learned?C J Logothetis, R J Amato
Pageof 43

Showing results (31-40 of 430) with videos related to

Sort By:
Pageof 43
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Is It Time to Re-Examine the Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases?Christopher J Logothetis, Ana M Aparicio
Nature Reviews. Cancer|January 5, 2005
Osteoblasts in prostate cancer metastasis to boneChristopher J Logothetis, Sue-Hwa Lin
Bibliotheca Psychiatrica|January 1, 1981
Side effects in preventive maintenance therapy with neuroleptics with special emphasis on tardive dyskinesiaJ Logothetis, A Paraschos, E Frangos
Cancer Research|August 4, 2004
Bortezomib as a potential treatment for prostate cancerChristos N Papandreou, Christopher J Logothetis
The American Journal of Psychiatry|February 1, 1981
The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapyN Manos, J Gkiouzepas, J Logothetis
Journal of the National Cancer Institute|July 22, 1998
Prospects for optimized clinical management of bladder cancer by application of phenotypic markersR E Millikan, C J Logothetis
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
High-grade prostate cancer and the prostate cancer prevention trialChristopher J Logothetis, Paul F Schellhammer
European Urology|March 27, 2024
Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7Christopher J Logothetis, Andrew W Hahn
European Urology|May 20, 2023
Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap SyndromeChristopher J Logothetis, Andrew W Hahn
Journal of the National Cancer Institute|November 18, 1992
Dose intensity in germ cell tumors: lessons learned?C J Logothetis, R J Amato
Pageof 43